@article{de7569b6b6614ed4804e2f0b7eb64d77,
title = "Association Between Intake of Red and Processed Meat and Survival in Patients With Colorectal Cancer in a Pooled Analysis",
abstract = "Background & Aims: Red and processed meat intake is associated with colorectal cancer (CRC) incidence, but it is not clear if intake is associated with patient survival after diagnosis. Methods: We pooled data from 7627 patients with stage I-IV CRC from 10 studies in the International Survival Analysis in Colorectal Cancer Consortium. Cox proportional hazards regression models were used to evaluate the associations of intake of red and processed meat before diagnosis with overall and CRC-specific survival. Results: Among 7627 patients with CRC, 2338 died, including 1576 from CRC, over a median follow-up time of 5.1 years. In multivariable-adjusted analyses, higher intake of red or processed meat was not associated with overall survival of patients with stage I–III CRC: Q4 vs Q1 red meat hazard ratio [HR], 1.08 (95% CI, 0.93–1.26) and Q4 vs Q1 processed meat HR, 1.10 (95% CI, 0.93–1.32) or with CRC-specific survival: Q4 vs Q1 red meat HR, 1.09 (95% CI, 0.89–1.33) and Q4 vs Q1 processed meat HR, 1.11 (95% CI, 0.87–1.42). Results were similar for patients with stage IV CRC. However, patients with stage I–III CRC who reported an intake of processed meat above the study-specific medians had a higher risk of death from any cause (HR, 1.12; 95% CI, 1.01–1.25) than patients who reported eating at or less than the median. Conclusion: In this large consortium of CRC patient cohorts, intake of red and processed meat before a diagnosis of CRC was not associated with shorter survival time after diagnosis, although a possible weak adverse association cannot be excluded. Studies that evaluate dietary data from several time points before and after cancer diagnosis are required to confirm these findings.",
keywords = "Colon Cancer, Epidemiology, ISACC, Risk Factor",
author = "Carr, {Prudence R.} and Banbury, {Barbara L.} and Berndt, {Sonja I.} and Campbell, {Peter T.} and Jenny Chang-Claude and Hayes, {Richard B.} and Howard, {Barbara V.} and Lina Jansen and Jacobs, {Eric J.} and Lane, {Dorothy S.} and Reiko Nishihara and Shuji Ogino and Phipps, {Amanda I.} and Slattery, {Martha L.} and Stefanick, {Marcia L.} and Robert Wallace and Viola Walter and Emily White and Kana Wu and Ulrike Peters and Chan, {Andrew T.} and Newcomb, {Polly A.} and Hermann Brenner and Michael Hoffmeister",
note = "Funding Information: The authors thank the CPS-II participants and Study Management Group for their invaluable contributions to this research. The authors would also like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, and cancer registries supported by the National Cancer Institute Surveillance Epidemiology and End Results program. The authors thank all participants and cooperating clinicians, and Ute Handte-Daub, Utz Benscheid, Muhabbet Celik and Ursula Eilber for excellent technical assistance. The authors would like to thank all those at the ISACC Coordinating Center for helping bring together the data and people that made this project possible. The authors would like to acknowledge Qin (Carolyn) Guo and Lixue Zhu who assisted in programming for NHS and HPFS, and Haiyan Zhang who assisted in programming for the PHS. We would like to thank the participants and staff of the Nurses' Health Study and the Health Professionals Follow-Up Study, for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data. The authors thank Drs Christine Berg and Philip Prorok, Division of Cancer Prevention, National Cancer Institute, the Screening Center investigators and staff or the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, Mr. Tom Riley and staff, Information Management Services, Inc., Ms. Barbara O{\textquoteright}Brien and staff, Westat, Inc., and Drs Bill Kopp and staff, SAIC-Frederick. Most importantly, we acknowledge the study participants for their contributions to making this study possible. The statements contained herein are solely those of the authors and do not represent or imply concurrence or endorsement by the National Cancer Institute. The authors thank the Women{\textquoteright}s Health Initiative investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: http://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Short%20List.pdf . Funding Information: Funding ISACC was supported by the National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services ( R01 CA176272 ). The Genetics and Epidemiology of Colorectal Cancer Consortium was supported by the National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services ( U01 CA137088 ; R01 CA059045 ). CCFR was supported by grant UM1 CA167551 from the National Cancer Institute and through cooperative agreements with the following CCFR centers: Seattle Colorectal Cancer Family Registry ( U01/U24 CA074794 ). The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II (CPS-II) cohort. This study was conducted with Institutional Review Board approval. DACHS was supported by the German Research Council (Deutsche Forschungsgemeinschaft, BR 1704/6-1 , BR 1704/6-3 , BR 1704/6-4 and CH 117/1-1 ), and the German Federal Ministry of Education and Research ( 01KH0404 , 01ER0814 , 01ER1505A , 01ER1505B ). DALS was supported by the National Institutes of Health ( R01 CA48998 to M. L. Slattery). HPFS is supported by the National Institutes of Health ( P01 CA 055075 , UM1 CA167552 , U01 CA167552 , R01 CA137178 , R01 CA151993 , R35 CA197735 , and P50 CA127003 ), NHS by the National Institutes of Health ( UM1 CA186107 , R01 CA137178 , P01 CA87969 , R01 CA151993 , R35 CA197735 , and P50 CA127003 ) and PHS by the National Institutes of Health ( R01 CA042182 ). PLCO was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services. VITAL was supported by the National Institutes of Health ( K05 CA154337 ). The Woman's Health Initiative program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C , HHSN268201100001C , HHSN268201100002C , HHSN268201100003C , HHSN268201100004C , and HHSN271201100004C . Publisher Copyright: {\textcopyright} 2019 AGA Institute",
year = "2019",
month = jul,
doi = "10.1016/j.cgh.2018.11.036",
language = "English (US)",
volume = "17",
pages = "1561--1570.e3",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "8",
}
